No difference in between-country variability in use of newly approved orphan and non- orphan medicinal products - a pilot study

BACKGROUND: Regulators and payers have to strike a balance between the needs of the patient and the optimal allocation of resources. Drugs indicated for rare diseases (orphan medicines) are a special group in this context because of their often high per unit costs. Our objective in this pilot study...

Descripción completa

Detalles Bibliográficos
Autores principales: Stolk, Pieter, Heemstra, Harald E, Leufkens, Hubert GM, Bloechl-Daum, Brigitte, Heerdink, Eibert R
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2805618/
https://www.ncbi.nlm.nih.gov/pubmed/20003427
http://dx.doi.org/10.1186/1750-1172-4-27

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2805618/
https://www.ncbi.nlm.nih.gov/pubmed/20003427
http://dx.doi.org/10.1186/1750-1172-4-27

Ejemplares similares